|
Technologies Available
for License
Standard Agreements
Invention Disclosure
Invention Agreement
Dartmouth Policies
Trademark Program
Annual Reports
Related Sites
|
|
Lung cancer is the leading
cause of cancer mortality for men and women in United States. Key molecular
changes, especially at early stages of carcinogenesis, represent potential
pharmacological targets for lung cancer chemoprevention and therapy. Aberrant
expression of cyclin E has been frequently observed in premalignant lung
lesions, indicating that this is an early step in lung carcinogenesis.
Overexpression of cyclin E also occurs in overt non-small cell lung cancers
(NSCLCs) and has prognostic significance in NSCLCs.
Dartmouth
researchers have now found that lung-specific overexpression of cyclin E in
epithelial cells promotes anchorage-independent cell growth, lung
hyperplasia, lung adenocarcinoma and local metastasis. Because lung
adenocarcinoma is a prevalent characteristic of human lung cancer, a
transgenic animal overexpressing cyclin E in lung epithelial cells now
provides a clinically relevant model system of human lung carcinogenesis for
the discovery and development of chemopreventive agents and therapeutic
agents for the prevention and treatment of lung cancer, including
premalignant lung lesions and overt non-small cell lung cancers.
This technology is claimed in
the issued United States Patent No. 7,586,022. We are seeking an industrial
partner interested in its commercialization. (Ref: J308)
|
